がん治療における低酸素細胞 : 問題点とその利用

概要

論文の詳細を見る
Hypoxic cells are radio-and chemo-resitant and are presented in a large proportion of human solid tumors. Many methods including direct measurement of tumor oxygenation by oxygen electrodes, immunohistochemical staining of nitroimidazoles or hypoxia related proteins, and detection using MRI or MRS, have been developed. Nitroimidazoles and nitrotriazoles can sensitize the response of hypoxic cells to irradiation. Tirapazamine, a bioreductive agent, is very toxic only to the hypoxic cells. Hypoxia stimulates angiogenesis and tumor development through the induction of proangiogenic proteins, such as vascular endothelial growth factor. A number of genes, including erythropoietin and various glycolytic enzymes, are also induced under hypoxic condition. Hypoxia-induceble factor 1 is a key protein in the process. New gene therapy vectors whose expression is selectively activated by a hypoxia have been developed. Although hypoxia is a major problem in cancer treatment, it is a new cancer treatment target.
新潟大学の論文
2003-10-10